Publications by authors named "A W Pike"

JC polyomavirus (JCPyV) establishes a persistent, asymptomatic kidney infection in most of the population. However, JCPyV can reactivate in immunocompromised individuals and cause progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease with no approved treatment. Mutations in the hypervariable non-coding control region (NCCR) of the JCPyV genome have been linked to disease outcomes and neuropathogenesis, yet few metanalyses document these associations.

View Article and Find Full Text PDF

Background: Genomics is a foundational element of precision health and can be used to identify inherited cancers, cancer related risks, therapeutic decisions, and to address health disparities. However, there are structural barriers across the cancer care continuum, including an underprepared nursing workforce, long wait times for service, and inadequate policy infrastructure that limit equitable access to the benefits of genomic discoveries. These barriers have persisted for decades, yet they are modifiable.

View Article and Find Full Text PDF

Sphingosine-1-phosphate (S1P) is a signaling lysolipid critical to heart development, immunity, and hearing. Accordingly, mutations in the S1P transporter SPNS2 are associated with reduced white cell count and hearing defects. SPNS2 also exports the S1P-mimicking FTY720-P (Fingolimod) and thereby is central to the pharmacokinetics of this drug when treating multiple sclerosis.

View Article and Find Full Text PDF

Background: Canada has the fourth highest per capita rate of opioid prescriptions in the world, contributing to the country's opioid crisis. Due to both their pain-relieving and euphoric properties, opioids can be highly addictive, leading to potential overdose and death. Deprescription is an endorsed and organized method of discontinuing a drug but very little is known about the barriers that Canadian physicians face when attempting to deprescribe opioids, particularly those who practice in rural areas (which have some of the highest rates of opioid users).

View Article and Find Full Text PDF

Affective biases are commonly seen in disorders such as depression and anxiety, where individuals may show attention towards and preferential processing of negative or threatening stimuli. Affective biases have been shown to change with effective intervention: randomized controlled trials into these biases and the mechanisms that underpin them may allow greater understanding of how interventions can be improved and their success be maximized. For such trials to be informative, we must have reliable ways of measuring affective bias over time, so we can detect how and whether they are altered by interventions: the test-retest reliability of our measures puts an upper bound on our ability to detect any changes.

View Article and Find Full Text PDF